In addition, Onpattro®, a recently approved liposomal therapy for the treatment of transthyretin-mediated (ATTR) amyloidosis, is a double-stranded siRNA formulated into lipid nanoparticles targeted to primary synthetic Hepatocytes at the site of TTR to inhibit the synthesis of TTR (Urits et al. 2020). Here, TTR is linked to amyloidosis.